Table 4 Mortality (all‐cause and cardiovascular disease) per 1000 person‐years, by Health Assessment Questionnaire groups at baseline and year 1, in rheumatic arthritis subgroup.
| Baseline HAQ | Year 1 HAQ | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| All (n = 728) | Followed‐up to first year (n = 698) | All (n = 698) | |||||||
| <1 | 1 to <2 | 2 to 3 | <1 | 1 to <2 | 2 to 3 | <1 | 1 to <2 | 2 to 3 | |
| HAQ group, n (%) | 347 (48) | 276 (38) | 105 (14) | 331 (47) | 268 (38) | 99 (14) | 393 (56) | 213 (31) | 92 (13) |
| Female, n (%) | 200 (58) | 200 (72) | 76 (72) | 193 (58) | 195 (73) | 72 (73) | 227 (58) | 159 (75) | 74 (80) |
| Median (IQR) age at onset (years) | 54 (43–64) | 56 (44–69) | 65 (53–73) | 54 (43–64) | 56 (44.5–69) | 65 (52–73) | 56 (44–65) | 55 (45–68) | 66 (51–73) |
| Median (IQR) swollen and tender joint count | 3 (1–7) | 7 (3–13) | 12 (5–19) | 3 (1–7) | 7 (3–13) | 11 (5–19) | 1 (0–2) | 3 (1–8) | 5 (2–12) |
| RF titre ⩾1:40 at baseline, n (%) | 121 (35) | 75 (27) | 38 (36) | 113 (34) | 74 (28) | 35 (35) | 129 (33) | 60 (28) | 33 (36) |
| RF titre ⩾1:80 at baseline, n (%) | 98 (28) | 64 (23) | 32 (30) | 92 (28) | 63 (24) | 30 (30) | 106 (27) | 51 (24) | 28 (30) |
| Satisfy ACR criteria at baseline, n (%) | 203 (59) | 196 (71) | 92 (88) | 189 (57) | 189 (71) | 86 (87) | 243 (62) | 146 (69) | 75 (82) |
| Mean (95% CI) DAS28 score | 3.87 (3.7 to 4) | 4.86 (4.7 to 5) | 5.61 (5.4 to 5.8) | 3.87 (3.7 to 4) | 4.86 (4.7 to 5) | 5.59 (5.4 to 5.8) | 4.18 (4.1 to 4.3) | 4.72 (4.6 to 4.9) | 5.3 (5.1 to 5.5) |
| Treated with DMARD by first year, n (%) | 162 (47) | 174 (63) | 74 (70) | 158 (48) | 173 (65) | 72 (73) | 209 (53) | 124 (58) | 70 (76) |
| All‐cause mortality rate per 1000 pyr over 10 years | 13.4 | 20.3 | 37.4 | 13.1 | 19.6 | 34.1 | 13.7 | 19.8 | 36.5 |
| CVD mortality rate per 1000 pyr >10 years | 8.8 | 9.5 | 20.5 | 8.6 | 8.9 | 18.6 | 7.6 | 10.6 | 19.8 |
ACR, American College of Rheumatology; CVD, cardiovascular disease; DAS28, Disease Activity score 28; DMARD, disease‐modifying anti‐rheumatic drug; HAQ, Health Assessment Questionnaire; HR, hazards ratio; pyr, person years; RF, rheumatoid factor.